Kelly Lawrence W & Associates Inc. CA Makes New $554,000 Investment in Edwards Lifesciences Corporation $EW

Kelly Lawrence W & Associates Inc. CA purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 6,125 shares of the medical research company’s stock, valued at approximately $554,000.

A number of other institutional investors have also modified their holdings of the company. Hanson & Doremus Investment Management purchased a new stake in Edwards Lifesciences in the 1st quarter worth approximately $25,000. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 3rd quarter worth $25,000. MV Capital Management Inc. purchased a new position in shares of Edwards Lifesciences during the 4th quarter worth $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences during the first quarter worth $26,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth $27,000. Institutional investors and hedge funds own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 23,145 shares of the firm’s stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the transaction, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. This trade represents a 19.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 25,570 shares of company stock worth $2,219,390. Company insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

EW has been the subject of several analyst reports. Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Barclays reaffirmed an “overweight” rating and set a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. TD Cowen reissued a “buy” rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Mizuho raised their target price on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Citigroup boosted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Price Performance

EW stock opened at $90.53 on Tuesday. The stock has a 50-day moving average price of $89.30 and a two-hundred day moving average price of $84.74. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a market cap of $52.13 billion, a PE ratio of 52.03, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.